Manufacturer Requested Reimbursement Criteria1:
An adjunct to a reduced calorie diet and increased physical
activity for chronic weight management in adult patients who have been
Obesity (BMI 30 kg/m2) AND prediabetes, or
Overweight (BMI 27 kg/m2 and 30 kg/m2) with one or
more weight-related comorbidity AND prediabetes.
Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.